Strados Labs

03/12/2026

What are the "big three" causes of chronic cough?

Chronic cough, typically defined as lasting more than eight weeks, is most often linked to three conditions: postnasal drip, asthma, and gastroesophageal reflux disease (GERD). Mucus drainage can trigger the cough reflex, asthma may present primarily as cough even without wheezing, and reflux can irritate the airway when stomach acid reaches the throat. Identifying the underlying driver is key to choosing the right treatment approach.

Because similar symptoms can arise from very different mechanisms, careful evaluation of cough patterns and progression can provide important clinical insight — and help inform both patient management and respiratory research.

Learn more from Houston Methodist: https://bit.ly/4aqezaz

Chronic cough is considered a lung disorder after eight weeks of persistent coughing. Contact Houston Methodist to learn more about the causes, symptoms, and treatment of chronic coughing. Find your pulmonologist at Houston Methodist.

03/10/2026

We’re looking forward to attending the Barcelona International Cough Conference (BICC), taking place March 20–21, 2026 in Barcelona and online!

BICC brings together clinicians, researchers, and industry leaders focused on advancing the science and clinical understanding of cough. Our Chief Commercial Officer Matthew McCarty and Director of Data Science Tom deLaubenfels will be attending on behalf of Strados.

Tune into our session on March 21st from 9:30 am - 9:45: Beyond cough frequency: applications of a multimodal acoustic monitoring platform, presented by Dr. deLaubenfels.

If you’ll be at BICC, we’d love the opportunity to connect and continue the conversation around objective measurement and digital approaches in respiratory research.

Learn more about the conference:
https://www.bicc.es/BICC24/en/home-en

03/04/2026

We're hiring!

As adoption of digital respiratory endpoints continues to grow in clinical research, we're expanding our commercial team.

We’re looking for a Director, Business Development – Respiratory Clinical Solutions to help deepen strategic partnerships with pharmaceutical and biotech sponsors and support multi-program collaborations across respiratory clinical trials.

This role will work closely with scientific, clinical, and operational stakeholders to advance the use of objective respiratory measurements in drug development.

If you have experience in respiratory medicine, pulmonary clinical research, or clinical trial solutions, we’d love to connect.

Know someone who might be a great fit? Feel free to share the opportunity.

🔗 Learn more and apply: https://www.linkedin.com/jobs/view/4379931410/

03/03/2026

Not all asthma patients present with wheeze or breathlessness.

Cough-variant asthma (CVA) is a form of asthma in which persistent cough may be the primary — and sometimes only — symptom, even without wheezing or shortness of breath. Despite this atypical presentation, CVA can involve airway hyperresponsiveness and inflammation similar to traditional asthma, making early recognition and treatment important.

For respiratory studies, presentations like CVA illustrate how meaningful symptoms can be overlooked when assessments rely only on episodic clinic visits or patient self-reporting. Objective cough measurement can help provide quantifiable evidence of symptom patterns and treatment response, supporting stronger endpoint strategies and a clearer understanding of disease impact.

Learn more in the Journal of Allergy and Clinical Immunology: https://www.jaci-inpractice.org/article/S2213-2198(24)01170-X/abstract

02/26/2026

Asthma affects more than 300 million people globally and remains a leading cause of pediatric emergency department visits and missed school days. Yet much of asthma management still relies on episodic assessments and patient-reported outcomes that can miss important insights.

The RESP® Platform is designed to support remote asthma monitoring by capturing objective, real-world measures of cough, wheeze, and breathing patterns—complementing pulmonary function tests and patient self-reporting to build a more complete picture of disease burden.

Learn more about RESP® for Asthma:
https://stradoslabs.com/therapeutic-areas-wearable-asthma-monitoring-device/

02/25/2026

Respiratory infections tend to rise in winter — and the reasons go beyond temperature alone.

Colder months bring more indoor time, closer contact, reduced ventilation, and lower humidity, all of which can make it easier for respiratory viruses to spread and persist. At the same time, multiple viruses often circulate together, adding complexity to seasonal illness patterns.

Recognizing these seasonal dynamics helps care teams anticipate risk and respond earlier. Capturing objective respiratory data over time can also help clinicians and researchers track symptom patterns, detect changes sooner, and better understand respiratory health during higher-risk periods.

Read more from Medical: https://www.news-medical.net/health/Why-Are-Respiratory-Infections-More-Common-in-Winter.aspx

Respiratory infection risk increases during winter due to a combination of environmental factors, seasonal immune changes, viral transmission dynamics, and behavioral shifts that collectively favor viral survival and spread. Understanding these interacting mechanisms enables more precise public heal...

02/17/2026

Digital health technologies are redefining respiratory care—expanding access through home monitoring and decentralized clinical trials that bring participation closer to patients.

A recent article from AJMC - The American Journal of Managed Care underscores both the promise and complexity of this shift. Experts agree that digital tools must be validated not only for accuracy, but also for how well they integrate into patients’ daily lives and clinical workflows. Learn more: https://bit.ly/4nJSd7w

Our clinically validated RESP® Biosensor reflects that approach. It continuously and passively captures lung sounds in a wireless, patient-friendly form factor that integrates into daily life. By collecting a robust combination of respiratory and physiological data, including time-stamped cough and wheeze events, it gives clinicians a more complete view of respiratory health in both care and research settings.

Digital health technologies enhance respiratory care through decentralized clinical trials and home monitoring, expanding access and improving patient engagement.

02/12/2026

We’re excited to welcome Matthew McCarty as Chief Commercial Officer at Strados Labs!

Matt brings nearly 20 years of experience across life sciences and clinical trials, including leadership roles at global CROs and senior executive experience in the clinical trial endpoint market. Throughout his career, he has partnered closely with pharmaceutical sponsors, biotechnology companies, and CROs to support the adoption of novel endpoints and decentralized data collection in global studies.

At Strados, Matt will lead sales, marketing, partnerships, and commercial strategy as we expand the RESP® Platform from objective cough and lung sound monitoring into a broader ecosystem of respiratory trial solutions.

From Matt: “I have long been impressed by the Strados Labs team and the RESP® Platform — not only for its technical innovation but for its clear differentiation in the clinical trial endpoint landscape. The ability to objectively and continuously measure cough and lung sounds addresses critical gaps in how respiratory diseases are evaluated in research today. I see tremendous opportunity to help sponsors integrate these solutions to generate more reliable data and ultimately improve the probability of clinical success.”

Please join us in welcoming Matt to the leadership team!

02/11/2026

Early detection and ongoing assessment continue to be central challenges in COPD care.

The 2026 update from the Global Initiative for Chronic Obstructive Lung Disease, summarized by Pulmonology Advisor, emphasizes earlier identification of disease progression, multimorbidity management, and the growing role of digital and AI-enabled approaches in COPD evaluation.

Read the update here: https://bit.ly/4qVEX1E

These priorities reinforce the need for tools that extend respiratory insight beyond episodic clinic visits—an area where continuous, real-world respiratory data may play an increasingly important role.

The GOLD COPD Update 2026 provides updated guidance on case-finding, disease activity, exacerbation management.

02/05/2026

In a recent conversation with Dr. Sabiha Hussain, MD, MPH, principal investigator of our cystic fibrosis study at Rutgers Robert Wood Johnson Medical School, we discussed the challenges of monitoring respiratory health in patients with cystic fibrosis once they leave the clinic.

Our discussion explored the limitations of episodic assessments, the importance of detecting subtle changes in lung health earlier, and why low-effort, home-based monitoring may be particularly meaningful for patients managing a chronic, high-burden disease like CF.

We also talked about how continuous lung sound monitoring could complement traditional measures such as FEV1 and patient-reported outcomes, and what it takes to design monitoring approaches that are both clinically relevant and realistic for patients to use over time.

Read the full Q&A with Dr. Hussain: https://stradoslabs.com/q-a-with-dr-sabiha-hussain-professor-of-medicine-at-robert-wood-johnson-medical-school-rutgers-health/

02/03/2026

Respiratory illness season remains a significant public health challenge, with influenza, COVID-19, and RSV continuing to drive hospitalizations and severe outcomes each year.

The Centers for Disease Control and Prevention recently released its Respiratory Illness Season Toolkit, designed to help public health partners, clinicians, and communities prepare for and respond to respiratory illness risk. The toolkit includes communication resources, prevention guidance, and materials to support education and outreach before and during peak respiratory virus season.

Explore the toolkit here: https://www.cdc.gov/respiratory-viruses/php/toolkit/index.html

As respiratory health continues to be a year-round concern, efforts that improve awareness, surveillance, and early insight into symptoms play an important role in protecting patients and supporting more proactive care.

A partner toolkit with essential respiratory illness resources and communication materials.

01/28/2026

Announcing COPD Exacerbation Study!

Amid persistently high readmission rates among patients with chronic obstructive pulmonary disease (COPD), we’re excited to announce a new observational research study in collaboration with Jefferson Health evaluating the use of our FDA 510(k) cleared RESP® Biosensor.

The SHORE study will assess the feasibility of continuous, home-based monitoring of cough and lung sounds (including wheeze and rhonchi) following COPD exacerbations. Enrollment started in January.

COPD exacerbations are a leading cause of hospitalization and readmission, yet clinicians often have limited insight into respiratory status once patients return home. The study will explore whether passive, stethoscope-based wearable monitoring can help extend respiratory assessment beyond the clinic and into daily life, where early changes may first appear.

Findings from the study are expected to inform future research into remote lung sound monitoring for COPD and other chronic respiratory diseases.

🔗 Read the full press release: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/strados-labs-announces-study-evaluating-remote-lung-sound-monitoring-1131102